Navigation Links
Tested a drug that strengthens the analgesic effect of opioids without increasing constipation
Date:3/31/2014

Scientists from the University of Granada have taken part, alongside the Esteve laboratory, in the development of a new drug that multiplies the analgesic effect of opioids (drugs for treating intense pain), without increasing constipation, one of the most common side-effects of these drugs, among which is morphine.

This important scientific breakthrough has been published in The Journal of Pharmacology and Experimental Therapeutics, and has been chosen as its outstanding article in the month of January. So far, the University of Granada researchers have published the results from testing this molecule on mice.

Opium derivates have been used since ancient times to treat pain. Currently, these and similar products (opioids) are the drugs used to treat various types of intense pain, such as post-operatory pain, cancer pain or internal-organ pain. The prolonged use of opioids causes strong constipation, which is a substantial drawback to their administration, since it substantially diminishes patient well-being.

The recently-published article proves that S1RA, a drug that blocks the sigma-1 receptor, manages to multiply solely the beneficial effect of the opioids; that is, their pain-killing properties.

The sigma-1 receptor is a very small protein that acts as a neuro-modulator, physically linking to other proteins (among which are the opioid receptors) and modifying their function.

As Enrique Cobos del Moral, one of the authors and a researcher at the University of Granada Institute of Neuroscience, explains, opioids are basically "centrally-acting" drugs; that is, they act directly upon the brain and the spinal medula. However, when opioids are associated with sigma-1 receptor blockers, their pain-killing effects are brought about by acting upon other areas; specifically, on the peripheral nervous system. From this, it is deduced that the sigma-1 receptor is a biological brake that prevents peripheral opioid analgesia, and that this brake can be eliminated by pharmacological treatment so as to increase the pain-killing power of opioids.

This scientific breakthrough is of huge importance for the well-being of patients suffering from pain, since, in the short term, it will allow the development of more efficient painkillers with fewer side-effects.

Esteve is working on the development of this medication, which is currently in Clinical Phase II


'/>"/>

Contact: Enrique J. Cobos del Moral
ejcobos@ugr.es
34-958-243-538
University of Granada
Source:Eurekalert  

Related medicine news :

1. Study questions anti-cancer mechanisms of drug tested in clinical trials
2. Data show drug being tested to reduce cardiovascular events increased risk of heart attack
3. Kirkman® Adds New Comprehensive Antioxidant to Ultra Tested® Product Line: Antioxidant/Cell Protect – Hypoallergenic
4. Brain Research Labs Brain Health And Performance News: Pioneer in the Field of Cognitive Performance and Health Succeeds with Clinically-Tested Natural Solutions
5. Fully Dissolvable, Temporary Stent for Opening Heart Artery Blockages Now Being Tested at The Mount Sinai Medical Center
6. Magellan Echo to Be Tested by Heart Rate Watch Company
7. Baron and Budd Supports the Newest Drug Being Tested for Mesothelioma Treatment
8. This Tested and Proven Ingredient Should be in Every Adults Daily Regime for Younger Skin, Says Sublime Beauty
9. SafeToSleep Baby Monitor Wins Parent Tested Parent Approved (PTPA) Award
10. Through New Innovative Measures, Highly Pathogenic Microbes Will Now Be Tested Clinically, Strengthening The Front Line In The Fight Against Food-Borne Illness
11. Handheld device for detecting counterfeit and substandard medicines tested by PQM
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tested a drug that strengthens the analgesic effect of opioids without increasing constipation
(Date:7/17/2019)... ... July 17, 2019 , ... Becker's Healthcare is pleased ... , The men and women included on this list lead organizations regularly recognized ... implementations as well as the construction of satellite clinics and strategic partnerships with ...
(Date:7/17/2019)... Ontario (PRWEB) , ... July 17, 2019 , ... ... management software and client engagement options for human services providers worldwide, has been ... , The CMAS program streamlines the procurement process for state and local government ...
(Date:7/17/2019)... ... 2019 , ... A new study led by researchers at the University of ... (JAMA), shows for the first time that New York’s sepsis protocols are directly responsible ... extreme response to infection. It kills more than 275,000 Americans each year and leaves ...
(Date:7/17/2019)... ... ... is pleased to announce a new office opening in Lapeer, Michigan. The office is ... corner of Turrill Road and South Lapeer Roads, conveniently off of I-69 in Lapeer. , ... office in Lapeer and the ability to service women in this community. We’ve dedicated ...
(Date:7/13/2019)... ... ... ZALO , the leading luxury sex toy manufacturer, is now shipping ... view the product and its accompanying video click here . , “We are ... around the world,” said Mara Epstein, director of sales. “The Hero provides a unique ...
Breaking Medicine News(10 mins):
(Date:7/18/2019)... Pa. (PRWEB) , ... July 18, 2019 , ... ... aimed at helping pharmaceutical companies reach meeting regulatory guidelines and achieve optimum TMF ... are Doing for TMF Health, Phlexglobal will host two Lunch and Learn events ...
(Date:7/17/2019)... , ... July 17, 2019 , ... ... its suite of CME subsidiaries: Global Learning Collaborative (GLC). , “The ... including growth in subsidiaries, scientific teams, leadership, and educational collaborations,” said Rob Braun, ...
(Date:7/17/2019)... ... July 17, 2019 , ... Updox ... to attract new customers, better engage existing patients and collaborate with prescribers, today ... services in tandem with an all-in-one platform. With the Updox approach, pharmacies are ...
Breaking Medicine Technology: